Skip to content
MarketScale
‹ Back to IndustriesHealthcare

AMAG Asks Symmetry Health Checks

AMAG Pharmaceuticals conducted a symmetry health check using software and technology tools to uncover hidden optimization opportunities within its existing pharmaceutical systems. The performance analysis examined system efficiency, workflow alignment, and process gaps. Findings point toward actionable improvements that can be achieved without full system replacement.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from AMAG on MarketScale.

By Software And Technology ·
Share

Key takeaways

01

Symmetry health checks identify optimization gaps in existing pharmaceutical software systems

02

Performance analysis can surface inefficiencies that routine operations typically obscure

03

Incremental system improvements are possible without full platform overhaul

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

This conversation, led by Kyle Gordon, EVP of Sales, Marketing and Commercial Excellence at AMAG, with Jeff LeBlanc and Scott Pressman from the professional services team. They discuss the concept of health checks for AMAG’s solutions, emphasizing how these checks help in understanding and optimizing system performance. The health check provides a user-friendly report identifying areas of concern and those that are functioning well, based on a comprehensive analysis of the system’s performance over a week and specific recommendations for improvement.

The health check provides a user-friendly report identifying areas of concern and those that are functioning well, based on a comprehensive analysis of the system’s performance over a week and specific recommendations for improvement.

AMAG

Part of this channel

AMAG

Physical access control and identity management for enterprise security.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

SA
Software And Technology

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

MRI segmentation models can now label 80 structures, but deployment is the hard part

MRI segmentation models can now label 80 structures. TotalSegmentator MRI is an nnU-Net model that provides rapid segmentation of all major organs across all MRI sequences, according to Radiology Business. For health systems, deployment is the hard part.

  • 01The spread between 0.97 Dice on lungs and 0.54 on portal and splenic veins in MRSegmentator is the real operational story: enterprises need confidence flags and escalation paths, not a single headline score.
  • 02Hospitals planning radiation oncology and neuro volumetry programs can treat segmentation speedups as capacity gains only if downstream steps, contour review, dose planning inputs, and reporting templates, are standardized.

Sep 8, 2026

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves screening at 50+ into primary care, with audiogram and amplification steps to follow

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

SA
Software And Technology

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512